Clinical trial
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With…
NCT00251680 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00251680 |
|---|---|
| Title | Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy. |
| Official title | A Placebo-Controlled, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in Subjects With Type 2 Diabetes Currently Treated With Lipid-Lowering Therapy |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy |
| Enrollment | 400 |
| Start date | Oct 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Nov 10, 2005 |
| Last update posted | May 24, 2012 |
| Countries | Czechia, Estonia, Finland, Germany, Poland, Slovakia, South Africa, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: